Form 13-F position report

SYNDAX PHARMACEUTICALS INC COM

Reported by WELLINGTON MANAGEMENT GROUP LLP

SNDX CUSIP 87164F105 Manager CIK 0000902219

Reported 34,085 shares, down 1,877 (5.2%) from the prior quarter.

Reported value -27.7%; share count -5.2% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 34,085 Quarter-end amount reported
Reported value $319,207 Fair value at quarter end
Consecutive quarters held 38 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 34997000
2022-03-31 31873000
2022-06-30 61699000
2022-09-30 105429000
2022-12-31 203178599
2023-03-31 147918861
2023-06-30 155806770
2023-09-30 110968316
2023-12-31 163916627
2024-03-31 176991461
2024-06-30 150669751
2024-09-30 95980040
2024-12-31 55979494
2025-03-31 441793
2025-06-30 319207
2025-09-30 588107
2025-12-31 748586
2026-03-31 2886969
2026-06-30 2715908
2026-09-30 1276427

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for SYNDAX PHARMACEUTICALS INC COM held by WELLINGTON MANAGEMENT GROUP LLP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 67,895 -56,346 (-45.4%) < 0.01% $1,276,427 2026-11-16
Q2 2026 Added 124,241 +655 (0.5%) < 0.01% $2,715,908 2026-08-14
Q1 2026 Added 123,586 +87,956 (246.9%) < 0.01% $2,886,969 2026-05-15
Q4 2025 Reduced 35,630 -2,596 (-6.8%) < 0.01% $748,586 2026-02-17
Q3 2025 Added 38,226 +4,141 (12.1%) < 0.01% $588,107 2025-11-14
Q2 2025 Reduced 34,085 -1,877 (-5.2%) < 0.01% $319,207 2025-08-14
Q1 2025 Reduced 35,962 -4,198,493 (-99.2%) < 0.01% $441,793 2025-05-13
Q4 2024 Reduced 4,234,455 -751,521 (-15.1%) 0.01% $55,979,494 2025-02-12
Q3 2024 Reduced 4,985,976 -2,353,028 (-32.1%) 0.02% $95,980,040 2024-11-14
Q2 2024 Reduced 7,339,004 -97,612 (-1.3%) 0.03% $150,669,751 2024-08-14
Q1 2024 Reduced 7,436,616 -148,605 (-2.0%) 0.03% $176,991,461 2024-05-15
Q4 2023 Reduced 7,585,221 -57,225 (-0.7%) 0.03% $163,916,627 2024-02-12
Q3 2023 Added 7,642,446 +198,262 (2.7%) 0.02% $110,968,316 2023-11-14
Q2 2023 Added 7,444,184 +440,450 (6.3%) 0.03% $155,806,770 2023-08-14
Q1 2023 Reduced 7,003,734 -979,708 (-12.3%) 0.03% $147,918,861 2023-05-12
Q4 2022 Added 7,983,442 +3,596,002 (82.0%) 0.04% $203,178,599 2023-02-13
Q3 2022 Added 4,387,440 +1,180,574 (36.8%) 0.02% $105,429,000 2022-11-14
Q2 2022 Added 3,206,866 +1,372,936 (74.9%) 0.01% $61,699,000 2022-08-15
Q1 2022 Added 1,833,930 +235,164 (14.7%) < 0.01% $31,873,000 2022-05-16
Q4 2021 Reduced 1,598,766 -78,093 (-4.7%) < 0.01% $34,997,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

250 managers reported SYNDAX PHARMACEUTICALS INC COM for Q2 2025.

Managers reporting SYNDAX PHARMACEUTICALS INC COM in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 10,456,907 +1,914,656 < 0.01% $97,928,939 4 qtrs
Kynam Capital Management LP Unchanged 8,520,000 0 8.59% $79,789,800 15 qtrs
The Goldman Sachs Group Inc Added 5,797,195 +1,875,654 < 0.01% $54,290,731 31 qtrs
VANGUARD GROUP INC Added 5,033,934 +162,869 < 0.01% $47,142,793 37 qtrs
Eversept Partners LP Reduced 4,065,355 -146,915 3.5% $38,072,050 13 qtrs
Bank of America Corporation Added 3,838,872 +967,873 < 0.01% $35,951,035 36 qtrs
STATE STREET CORPORATION Reduced 3,442,752 -528,980 < 0.01% $32,241,373 37 qtrs
STEMPOINT CAPITAL LP Added 2,372,634 +774,040 7.13% $22,219,717 7 qtrs
FRANKLIN RESOURCES INC Added 2,359,677 +298,272 < 0.01% $22,098,378 7 qtrs
Point72 Asset Management L P Reduced 2,127,467 -1,881,233 0.04% $19,923,729 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
30,504
None
3,581

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.